National Bank of Canada FI Grows Holdings in Charles River Laboratories International, Inc. $CRL

National Bank of Canada FI lifted its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 42.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,987 shares of the medical research company's stock after acquiring an additional 10,132 shares during the quarter. National Bank of Canada FI owned 0.07% of Charles River Laboratories International worth $5,116,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Two Sigma Securities LLC lifted its position in shares of Charles River Laboratories International by 4.3% in the 4th quarter. Two Sigma Securities LLC now owns 1,981 shares of the medical research company's stock worth $366,000 after purchasing an additional 81 shares during the period. Wahed Invest LLC increased its holdings in Charles River Laboratories International by 6.5% during the fourth quarter. Wahed Invest LLC now owns 1,321 shares of the medical research company's stock valued at $244,000 after buying an additional 81 shares during the period. Teachers Retirement System of The State of Kentucky increased its holdings in Charles River Laboratories International by 2.7% during the first quarter. Teachers Retirement System of The State of Kentucky now owns 3,916 shares of the medical research company's stock valued at $589,000 after buying an additional 102 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Charles River Laboratories International by 2.6% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,131 shares of the medical research company's stock valued at $763,000 after buying an additional 105 shares during the period. Finally, Veracity Capital LLC increased its holdings in Charles River Laboratories International by 3.4% during the first quarter. Veracity Capital LLC now owns 3,298 shares of the medical research company's stock valued at $496,000 after buying an additional 107 shares during the period. 98.91% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 400 shares of the business's stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $150.04, for a total transaction of $60,016.00. Following the completion of the transaction, the executive vice president directly owned 24,916 shares in the company, valued at $3,738,396.64. The trade was a 1.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.30% of the stock is owned by corporate insiders.

Charles River Laboratories International Stock Performance

Shares of NYSE:CRL traded up $0.59 on Monday, hitting $157.27. 130,713 shares of the company were exchanged, compared to its average volume of 1,277,696. Charles River Laboratories International, Inc. has a 1-year low of $91.86 and a 1-year high of $230.02. The stock's 50 day moving average price is $156.87 and its 200 day moving average price is $148.74. The company has a current ratio of 1.36, a quick ratio of 1.10 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $7.74 billion, a P/E ratio of -118.25, a price-to-earnings-growth ratio of 5.00 and a beta of 1.48.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The medical research company reported $3.12 EPS for the quarter, topping the consensus estimate of $2.50 by $0.62. Charles River Laboratories International had a negative net margin of 1.69% and a positive return on equity of 15.74%. The business had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $983.76 million. During the same period in the previous year, the firm posted $2.80 earnings per share. The business's revenue for the quarter was up .6% compared to the same quarter last year. Sell-side analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Analyst Upgrades and Downgrades

CRL has been the topic of several research reports. Citigroup raised shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $150.00 to $200.00 in a report on Wednesday, July 9th. Redburn Atlantic raised shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and cut their price objective for the company from $188.00 to $182.00 in a report on Friday, May 23rd. Barclays lifted their price objective on shares of Charles River Laboratories International from $155.00 to $165.00 and gave the company an "equal weight" rating in a report on Thursday, August 7th. Evercore ISI lifted their price objective on shares of Charles River Laboratories International from $180.00 to $190.00 and gave the company an "outperform" rating in a report on Friday, August 8th. Finally, Cowen raised shares of Charles River Laboratories International from a "hold" rating to a "buy" rating in a report on Wednesday, May 14th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat.com, Charles River Laboratories International has an average rating of "Hold" and an average price target of $175.69.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).